Acetaminophen Dextromethorphan Hydrobromide Guaife

證據等級: L5

預測適應症: 0 個

ACETAMINOPHEN / DEXTROMETHORPHAN / GUAIFENESIN / PSEUDOEPHEDRINE: Combination Cold Relief Agent — No Repurposing Prediction Generated

One-Sentence Summary

This four-component OTC combination (analgesic + antitussive + expectorant + decongestant) is a classic cold and flu symptom-relief product widely used globally. The TxGNN model did not generate any new indication predictions for this combination — most likely because TxGNN operates on single molecular entities, and this multi-ingredient compound lacks a unified DrugBank ID. Due to the absence of predictions, Taiwan regulatory data, and safety records, no repurposing evaluation can be completed at this stage.

Quick Overview

Item	Content
Original Indication	Cold/flu symptom relief (analgesic, antitussive, expectorant, nasal decongestant — based on known pharmacology of the four components)
Predicted New Indication	None (TxGNN returned no predictions)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction unavailable; no supporting studies identified
US Market Status	Not marketed in Taiwan (0 licenses on record)
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This entry contains four distinct active pharmaceutical ingredients rather than a single molecular entity:

Component	Drug Class	Role in Combination
Acetaminophen	Analgesic / Antipyretic	Reduces fever and pain
Dextromethorphan HBr	Antitussive (NMDA antagonist)	Suppresses cough reflex
Guaifenesin	Expectorant	Thins and loosens mucus
Pseudoephedrine	Sympathomimetic decongestant	Reduces nasal congestion

TxGNN is designed to generate predictions for individual drug nodes in its knowledge graph, each identified by a unique DrugBank ID. Because this combination has no single DrugBank ID (drugbank_id: null), the model cannot map it to the graph and therefore produces no repurposing candidates.

To run a meaningful TxGNN analysis, each component would need to be evaluated individually, and any overlapping predictions across all four components could then be considered combinatorial opportunities.

Safety Considerations

Please refer to the package insert for safety information.

No warning, contraindication, or drug-drug interaction data was retrieved for this combination entry. Each component individually carries well-known safety profiles (e.g., pseudoephedrine contraindicated in hypertension; acetaminophen risk in hepatic impairment; dextromethorphan interaction with MAO inhibitors), but these could not be formally captured under the current drugbank_id: null query pathway.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN cannot process multi-ingredient combinations without individual DrugBank node identifiers; zero predictions were generated, and Taiwan regulatory and safety records are both absent, making a repurposing evaluation impossible at this stage.

To proceed, the following is needed:

Decompose the combination: Run TxGNN separately for each of the four components using their individual DrugBank IDs:
- Acetaminophen → DB00316
- Dextromethorphan → DB00514
- Guaifenesin → DB00806
- Pseudoephedrine → DB00852
Aggregate component-level predictions: Identify diseases that appear in the top predictions for two or more components simultaneously, as these represent the most actionable combinatorial repurposing signals
Retrieve Taiwan regulatory status per component: Each ingredient may have individual TFDA licenses even if the fixed-dose combination does not
Obtain safety data: Query DrugBank API per component to retrieve MOA, warnings, contraindications, and DDI profiles
Determine regulatory pathway: If a repurposing candidate is identified, clarify whether it requires a new NDA for the combination or whether individual component data is sufficient for bridging
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.